Complexa: First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA10 to Treat a Rare and Severe Form of Kidney Disease Focal Segmental Glomerulosclerosis

Complexa Inc. today announced dosing of the first patient in FIRSTx a Phase 2 clinical trial evaluating the safety and efficacy of the companys lead candidate CXA10 to treat primary focal segmental glomerulosclerosis FSGS. FSGS is a...